Vaxart Announces Publication Of Preclinical Study Results Evaluating Its Oral Mucosal Vaccine Platform Against Highly Pathogenic Avian Influenza H5N1; Candidate VXA-H5-02 Induced Robust Cross-Neutralizing Antibodies
Publication of positive preclinical study results evaluating its adenovirus-based oral mucosal vaccine platform against Highly Pathogenic Avian Influenza (HPAI) H5N1, a pathogenic virus that poses a significant threat